TY - JOUR
T1 - Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
AU - Casanova, Ciro
AU - Celli, Bartolome R.
AU - de-Torres, Juan P.
AU - Martínez-Gonzalez, Cristina
AU - Cosio, Borja G.
AU - Pinto-Plata, Victor
AU - de Lucas-Ramos, Pilar
AU - Divo, Miguel
AU - Fuster, Antonia
AU - Peces-Barba, Germán
AU - Calle-Rubio, Myriam
AU - Solanes, Ingrid
AU - Aguero, Ramón
AU - Feu-Collado, Nuria
AU - Alfageme, Inmaculada
AU - De Diego, Alfredo
AU - Romero, Amparo
AU - Balcells, Eva
AU - Llunell, Antonia
AU - Galdiz, Juan B.
AU - Marin, Margarita
AU - Moreno, Amalia
AU - Cabrera, Carlos
AU - Golpe, Rafael
AU - Lacarcel, Celia
AU - Soriano, Joan B.
AU - López-Campos, José Luis
AU - Soler-Cataluña, Juan J.
AU - Marin, José M.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Copyright ©ERS 2017. The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels <300 cells·μL-1 A similar eosinophil blood pattern was observed in controls. Exacerbation rates did not differ in patients with and without eosinophilia. All-cause mortality was lower in patients with high eosinophils compared with those with values <300 cells·μL-1 (15.8% versus 33.7%; p=0.026).In patients with COPD, blood eosinophils ≥300 cells·μL-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.
AB - Copyright ©ERS 2017. The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels <300 cells·μL-1 A similar eosinophil blood pattern was observed in controls. Exacerbation rates did not differ in patients with and without eosinophilia. All-cause mortality was lower in patients with high eosinophils compared with those with values <300 cells·μL-1 (15.8% versus 33.7%; p=0.026).In patients with COPD, blood eosinophils ≥300 cells·μL-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.
U2 - 10.1183/13993003.01162-2017
DO - 10.1183/13993003.01162-2017
M3 - Article
SN - 0903-1936
VL - 50
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 5
ER -